Activation, coactivation, and costimulation of resting human natural killer cells

Immunological Reviews

Volumn 214, Issue 1, 2006, Pages 73-91

  Bryceson, Yenan T ^a,b   March, Michael E ^a   Ljunggren, Hans Gustaf ^b   Long, Eric O ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Innate immunity; Natural killer cell; Signaling; Synergy

Indexed keywords

ADECATUMUMAB; ALEMTUZUMAB; CD16 ANTIGEN; FC RECEPTOR; GAMMA INTERFERON; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UVOMORULIN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; B CELL LEUKEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; BINDING AFFINITY; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL ADHESION; CELL POLARITY; CELL SPECIFICITY; CELL STIMULATION; CELL SUBPOPULATION; CYTOSKELETON; CYTOTOXICITY; CYTOTOXICITY TEST; DEGRANULATION; DROSOPHILA; GENETIC ASSOCIATION; GOLGI COMPLEX; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IMMUNOTHERAPY; INNATE IMMUNITY; LEUKOCYTE FUNCTION; LIGAND BINDING; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE MIGRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA CELL; MICROTUBULE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; XENOGRAFT;

G0 PHASE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION;

EID: 33750694590     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2006.00457.x     Document Type: Review

References (199)

1. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-274.
2. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002;2:735-747.
3. Bossi G, Griffiths GM. CTL secretory lysosomes: biogenesis and secretion of a harmful organelle. Semin Immunol 2005;17:87-94.
4. O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol 2002;2:37-45.
5. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003;21:713-758.
6. Rock KL, York IA, Saric T, Goldberg AL. Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 2002;80:1-70.
7. Dorman SE, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004;364:2113-2121.
8. Novelli F, Casanova JL. The role of IL-12, IL-23 and IFN-gamma in immunity to viruses. Cytokine Growth Factor Rev 2004;15:367-377.
9. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 2000;97:2731-2736.
10. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-360.
11. Wallace ME, Smyth MJ. The role of natural killer cells in tumor control - effectors and regulators of adaptive immunity. Springer Semin Immunopathol 2005;27:49-64.
12. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999;17:189-220.
13. Shi FD, et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 2000;1:245-251.
14. Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 2005;202:203-207.
15. Zitvogel L, Terme M, Borg C, Trinchieri G. Dendritic cell-NK cell cross-talk: regulation and physiopathology. Curr Top Microbiol Immunol 2006;298:157-174.
16. Perussia B. Fc receptors on natural killer cells. Curr Top Microbiol Immunol 1998;230:63-88.
17. MurphyWJ, Koh CY, Raziuddin A, Bennett M, Longo DL. Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies. Immunol Rev 2001;181:279-289.
18. Ruggeri L, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100.
19. Parham P, McQueen KL. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol 2003;3:108-122.
20. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005;17:211-217.
21. Billadeau DD, Leibson PJ. ITAMs versus ITIMs: striking a balance during cell regulation. J Clin Invest 2002;109:161-168.
22. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science 2004;306:1517-1519.
23. Zompi S, Colucci F. Anatomy of a murder - signal transduction pathways leading to activation of natural killer cells. Immunol Lett 2005;97:31-39.
24. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990;11:237-244.
25. Kelley J, Walter L, Trowsdale J. Comparative genomics of natural killer cell receptor gene clusters. PLoS Genet 2005;1:129-139.
26. Burshtyn DN, et al. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 1996;4:77-85.
27. Binstadt BA, et al. Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity 1996;5:629-638.
28. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 2000;290:84-89.
29. Braud VM, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998;391:795-799.
30. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998;187:813-818.
31. Lee N, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 1998;95:5199-5204.
32. Colonna M, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997;186:1809-1818.
33. Chapman TL, Heikeman AP, Bjorkman PJ. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity 1999;11:603-613.
34. Yokoyama WM, Kim S. How do natural killer cells find self to achieve tolerance? Immunity 2006;24:249-257.
35. Raulet DH. Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol 2006;18:145-150.
36. Liao NS, Bix M, Zijlstra M, Jaenisch R, Raulet D. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 1991;253:199-202.
37. Hoglund P, et al. Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice. Proc Natl Acad Sci USA 1991;88:10332-10336.
38. Ljunggren HG, Van Kaer L, Ploegh HL, Tonegawa S. Altered natural killer cell repertoire in Tap-1 mutant mice. Proc Natl Acad Sci USA 1994;91:6520-6524.
39. Zimmer J, et al. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med 1998;187:117-122.
40. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005;105:4416-4423.
41. Kim S, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005;436:709-713.
42. Johansson S, et al. Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J Exp Med 2005;201:1145-1155.
43. Butcher S, Arney KL, Cook GP. MAFA-L, an ITIM-containing receptor encoded by the human NK cell gene complex and expressed by basophils and NK cells. Eur J Immunol 1998;28:3755-3762.
44. Voehringer D, Koschella M, Pircher H. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). Blood 2002;100:3698-3702.
45. Grundemann C, et al. Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol 2006;176:1311-1315.
46. Ito M, Maruyama T, Saito N, Koganei S, Yamamoto K, Matsumoto N. Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J Exp Med 2006;203:289-295.
47. Iizuka K, Naidenko OV, Plougastel BF, Fremont DH, Yokoyama WM. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat Immunol 2003;4:801-807.
48. Carlyle JR, Jamieson AM, Gasser S, Clingan CS, Arase H, Raulet DH. Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors. Proc Natl Acad Sci USA 2004;101:3527-3532.
49. Aldemir H, et al. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol 2005;175:7791-7795.
50. Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, Lanier LL. Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 2005;175:7796-7799.
51. Nicoll G, et al. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J Biol Chem 1999;274:34089-34095.
52. Zhang JQ, Nicoll G, Jones C, Crocker PR. Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. J Biol Chem 2000;275:22121-22126.
53. Avril T, Floyd H, Lopez F, Vivier E, Crocker PR. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J Immunol 2004;173:6841-6849.
54. Cantoni C, et al. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur J Immunol 1999;29:3148-3159.
55. Storkus WJ, Dawson JR. Target structures involved in natural killing (NK): characteristics, distribution, and candidate molecules. Crit Rev Immunol 1991;10:393-416.
56. Bottino C, Castriconi R, Moretta L, Moretta A. Cellular ligands of activating NK receptors. Trends Immunol 2005;26:221-226.
57. Stewart CA, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 2005;102:13224-13229.
58. Kaiser BK, Barahmand-Pour F, Paulsene W, Medley S, Geraghty DE, Strong RK. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol 2005;174:2878-2884.
59. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002;296:1323-1326.
60. Abi-Rached L, Parham P. Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. J Exp Med 2005;201:1319-1332.
61. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 2001;276:16469-16477.
62. Moretta A, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
63. Bottino C, Moretta L, Pende D, Vitale M, Moretta A. Learning how to discriminate between friends and enemies, a lesson from natural killer cells. Mol Immunol 2004;41:569-575.
64. Mandelboim O, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001;409:1055-1060.
65. Arnon TI, et al. The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood 2004;103:664-672.
66. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006;107:159-166.
67. Pasquier B, et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 2005;22:31-42.
68. Hamerman JA, Lanier LL. Inhibition of immune responses by ITAM-bearing receptors. Sci STKE 2006;2006:re1.
69. Colucci F, et al. Natural cytotoxicity uncoupled fromthe Syk and ZAP-70 intracellular kinases. Nat Immunol 2002;3:288-294.
70. Chiesa S, et al. Multiplicity and plasticity of natural killer cell signaling pathways. Blood 2006;107:2364-2372.
71. Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol 2006;7:524-532.
72. Cerwenka A, Lanier LL. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 2003;61:335-343.
73. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005;436:1186-1190.
74. Chen R, et al. Molecular dissection of 2B4 signaling: implications for signal transduction by SLAM-related receptors. Mol Cell Biol 2004;24:5144-5156.
75. Eissmann P, Beauchamp L, Wooters J, Tilton JC, Long EO, Watzl C. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood 2005;105:4722-4729.
76. Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med 1998;188:2083-2090.
77. Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol 2002;39:1-8.
78. Falco M, et al. Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells. Eur J Immunol 2004;34:1663-1672.
79. Flaig RM, Stark S, Watzl C. Cutting edge: NTB-A activates NK cells via homophilic interaction. J Immunol 2004;172:6524-6527.
80. Shibuya K, et al. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity 1999;11:615-623.
81. Shibuya A, Lanier LL, Phillips JH. Protein kinase C is involved in the regulation of both signaling and adhesion mediated by DNAX accessory molecule-1 receptor. J Immunol 1998;161:1671-1676.
82. Bottino C, et al. Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003;198:557-567.
83. Bauer S, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
84. Pende D, et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001;31:1076-1086.
85. Lanier LL, Corliss B, Phillips JH. Arousal and inhibition of human NK cells. Immunol Rev 1997;155:145-154.
86. Valiante NM, Trinchieri G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J Exp Med 1993;178:1397-1406.
87. Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M. Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol 2001;167:5517-5521.
88. Lyman SD, Escobar S, Rousseau AM, Armstrong A, Fanslow WC. Identification of CD7 as a cognate of the human K12 (SECTM1) protein. J Biol Chem 2000;275:3431-3437.
89. Pace KE, Hahn HP, Pang M, Nguyen JT, Baum LG. CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. J Immunol 2000;165:2331-2334.
90. Rabinowich H, Pricop L, Herberman RB, Whiteside TL. Expression and function of CD7 molecule on human natural killer cells. J Immunol 1994;152:517-526.
91. Galandrini R, De Maria R, Piccoli M, Frati L, Santoni A. CD44 triggering enhances human NK cell cytotoxic functions. J Immunol 1994;153:4399-4407.
92. Sconocchia G, Titus JA, Segal DM. CD44 is a cytotoxic triggering molecule in human peripheral blood NK cells. J Immunol 1994;153:5473-5481.
93. Marcenaro E, et al. CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity. Eur J Immunol 2003;33:3367-3376.
94. Faure M, Long EO. KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J Immunol 2002;168:6208-6214.
95. Kikuchi-Maki A, Catina TL, Campbell KS. Cutting edge: KIR2DL4 transduces signals into human NK cells through association with the Fc receptor g protein. J Immunol 2005;174:3859-3863.
96. Rajagopalan S, et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 2006;4:e9.
97. Rajagopalan S, Fu J, Long EO. Cutting edge: induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells. J Immunol 2001;167:1877-1881.
98. Barakonyi A, et al. Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. J Immunol 2004;173:5349-5354.
99. Wang J, Springer TA. Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses. Immunol Rev 1998;163:197-215.
100. Krensky AM, Sanchez-Madrid F, Robbins E, Nagy JA, Springer TA, Burakoff SJ. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. J Immunol 1983;131:611-616.
101. Hildreth JE, Gotch FM, Hildreth PD, McMichael AJ. A human lymphocyte-associated antigen involved in cell-mediated lympholysis. Eur J Immunol 1983;13:202-208.
102. Miedema F, Tetteroo PA, Hesselink WG, Werner G, Spits H, Melief CJ. Both Fc receptors and lymphocyte-function-associated antigen 1 on human T gamma lymphocytes are required for antibody-dependent cellular cytotoxicity (killer cell activity). Eur J Immunol 1984;14:518-523.
103. Lanier LL, Ruitenberg JJ, Phillips JH. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol 1988;141:3478-3485.
104. Gismondi A, Morrone S, Humphries MJ, Piccoli M, Frati L, Santoni A. Human natural killer cells express VLA-4 and VLA-5, which mediate their adhesion to fibronectin. J Immunol 1991;146:384-392.
105. Mainiero F, et al. RAC1/P38 MAPK signaling pathway controls beta1 integrin-induced interleukin-8 production in human natural killer cells. Immunity 2000;12:7-16.
106. Gismondi A, et al. Proline-rich tyrosine kinase-2 activation by beta 1 integrin fibronectin receptor cross-linking and association with paxillin in human natural killer cells. J Immunol 1997;159:4729-4736.
107. Palmieri G, et al. Cross-linking of alpha 4 beta 1 and alpha 5 beta 1 fibronectin receptors enhances natural killer cell cytotoxic activity. J Immunol 1995;155:5314-5322.
108. Milella M, et al. Beta 1 integrin cross-linking inhibits CD16-induced phospholipase D and secretory phospholipase A2 activity and granule exocytosis in human NK cells: role of phospholipase D in CD16-triggered degranulation. J Immunol 1999;162:2064-2072.
109. Rose DM, Liu S, Woodside DG, Han J, Schlaepfer DD, Ginsberg MH. Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol 2003;170:5912-5918.
110. Hogg N, Henderson R, Leitinger B, McDowall A, Porter J, Stanley P. Mechanisms contributing to the activity of integrins on leukocytes. Immunol Rev 2002;186:164-171.
111. Barber DF, Long EO. Coexpression of CD58 or CD48 with intercellular adhesion molecule 1 on target cells enhances adhesion of resting NK cells. J Immunol 2003;170:294-299.
112. Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med 2005;202:1001-1012.
113. Matsumoto G, Nghiem MP, Nozaki N, Schmits R, Penninger JM. Cooperation between CD44 and LFA-1/CD11a adhesion receptors in lymphokine-activated killer cell cytotoxicity. J Immunol 1998;160:5781-5789.
114. Kim M, Carman CV, Springer TA. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 2003;301:1720-1725.
115. Kinashi T. Intracellular signaling controlling integrin activation in lymphocytes. Nat Rev Immunol 2005;5:546-559.
116. Stewart MP, McDowall A, Hogg N. LFA-1-mediated adhesion is regulated by cytoskeletal restraint and by a Ca2+-dependent protease, calpain. J Cell Biol 1998;140:699-707.
117. Franco SJ, et al. Calpain-mediated proteolysis of talin regulates adhesion dynamics. Nat Cell Biol 2004;6:977-983.
118. Fagerholm SC, Hilden TJ, Gahmberg CG. P marks the spot: site-specific integrin phosphorylation regulates molecular interactions. Trends Biochem Sci 2004;29:504-512.
119. Kiema T, et al. The molecular basis of filamin binding to integrins and competition with talin. Mol Cell 2006;21:337-347.
120. Fagerholm SC, Hilden TJ, Nurmi SM, Gahmberg CG. Specific integrin alpha and beta chain phosphorylations regulate LFA-1 activation through affinity-dependent and -independent mechanisms. J Cell Biol 2005;171:705-715.
121. Katagiri K, Maeda A, Shimonaka M, Kinashi T. RAPL, a Rap1-binding molecule that mediates Rap1-induced adhesion through spatial regulation of LFA-1. Nat Immunol 2003;4:741-748.
122. Carpen O, Virtanen I, Saksela E. Ultrastructure of human natural killer cells: nature of the cytolytic contacts in relation to cellular secretion. J Immunol 1982;128:2691-2697.
123. Carpen O, Virtanen I, Lehto VP, Saksela E. Polarization of NK cell cytoskeleton upon conjugation with sensitive target cells. J Immunol 1983;131:2695-2698.
124. Kupfer A, Dennert G, Singer SJ. Polarization of the Golgi apparatus and the microtubule-organizing center within cloned natural killer cells bound to their targets. Proc Natl Acad Sci USA 1983;80:7224-7228.
125. Wulfing C, Purtic B, Klem J, Schatzle JD. Stepwise cytoskeletal polarization as a series of checkpoints in innate but not adaptive cytolytic killing. Proc Natl Acad Sci USA 2003;100:7767-7772.
126. Kupfer A, Singer SJ. Cell biology of cytotoxic and helper T cell functions: immunofluorescence microscopic studies of single cells and cell couples. Annu Rev Immunol 1989;7:309-337.
127. Barber DF, Faure M, Long EO. LFA-1 contributes an early signal for NK cell cytotoxicity. J Immunol 2004;173:3653-3659.
128. Billadeau DD, Brumbaugh KM, Dick CJ, Schoon RA, Bustelo XR, Leibson PJ. The Vav-Rac1 pathway in cytotoxic lymphocytes regulates the generation of cell-mediated killing. J Exp Med 1998;188:549-559.
129. Jiang K, et al. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 2000;1:419-425.
130. Riteau B, Barber DF, Long EO. Vav1 phosphorylation is induced by beta2 integrin engagement on natural killer cells upstream of actin cytoskeleton and lipid raft reorganization. J Exp Med 2003;198:469-474.
131. Gismondi A, et al. Proline-rich tyrosine kinase 2 and Rac activation by chemokine and integrin receptors controls NK cell transendothelial migration. J Immunol 2003;170:3065-3073.
132. Sanchez-Martin L, et al. Signaling through the leukocyte integrin LFA-1 in T cells induces a transient activation of Rac-1 that is regulated by Vav and PI3K/Akt-1. J Biol Chem 2004;279:16194-16205.
133. Bernardini G, Kim JY, Gismondi A, Butcher EC, Santoni A. Chemoattractant induces LFA-1 associated PI 3K activity and cell migration that are dependent on Fyn signaling. FASEB J 2005;19:1305-1307.
134. Huang J, Tilly D, Altman A, Sugie K, Grey HM. T-cell receptor antagonists induce Vav phosphorylation by selective activation of Fyn kinase. Proc Natl Acad Sci USA 2000;97:10923-10929.
135. Nishida K, et al. FceRI-mediated mast cell degranulation requires calcium-independent microtubule-dependent translocation of granules to the plasma membrane. J Cell Biol 2005;170:115-126.
136. Martin-Cofreces NB, et al. Role of Fyn in the rearrangement of tubulin cytoskeleton induced through TCR. J Immunol 2006;176:4201-4207.
137. Lowin-Kropf B, Kunz B, Schneider P, Held W. A role for the src family kinase Fyn in NK cell activation and the formation of the repertoire of Ly49 receptors. Eur J Immunol 2002;32:773-782.
138. Jacobs R, et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 2001;31:3121-3127.
139. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004;294:15-22.
140. Perez OD, Mitchell D, Jager GC, Nolan GP. LFA-1 signaling through p44/42 is coupled to perforin degranulation in CD56+CD8+ natural killer cells. Blood 2004;104:1083-1093.
141. da Silva AJ, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol 2002;168:4462-4471.
142. Johnston SC, Dustin ML, Hibbs ML, Springer TA. On the species specificity of the interaction of LFA-1 with intercellular adhesion molecules. J Immunol 1990;145:1181-1187.
143. Ting AT, Schoon RA, Abraham RT, Leibson PJ. Interaction between protein kinase C-dependent and G protein-dependent pathways in the regulation of natural killer cell granule exocytosis. J Biol Chem 1992;267:23957-23962.
144. Liu D, Xu L, Yang F, Li D, Gong F, Xu T. Rapid biogenesis and sensitization of secretory lysosomes in NK cells mediated by target-cell recognition. Proc Natl Acad Sci USA 2005;102:123-127.
145. Wang D, et al. Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors. Immunity 2000;13:25-35.
146. Tassi I, Presti R, Kim S, Yokoyama WM, Gilfillan S, Colonna M. Phospholipase C-g2 is a critical signaling mediator for murine NK cell activating receptors. J Immunol 2005;175:749-754.
147. Caraux A, et al. Phospholipase C-gamma2 is essential for NK cell cytotoxicity and innate immunity to malignant and virally infected cells. Blood 2006;107:994-1002.
148. Upshaw JL, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. The isoforms of phospholipase C-gamma are differentially used by distinct human NK activating receptors. J Immunol 2005;175:213-218.
149. Ferlazzo G, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004;172:1455-1462.
150. Fehniger TA, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003;101:3052-3057.
151. Kohl S, Loo LS, Schmalstieg FS, Anderson DC. The genetic deficiency of leukocyte surface glycoprotein Mac-1, LFA-1, p150, 95 in humans is associated with defective antibody-dependent cellular cytotoxicity in vitro and defective protection against herpes simplex virus infection in vivo. J Immunol 1986;137:1688-1694.
152. Inwald D, Davies EG, Klein N. Demystified adhesion molecule deficiencies. Mol Pathol 2001;54:1-7.
153. Bunting M, Harris ES, McIntyre TM, Prescott SM, Zimmerman GA. Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving beta 2 integrins and selectin ligands. Curr Opin Hematol 2002;9:30-35.
154. Anderson DC, et al. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J Infect Dis 1985;152:668-689.
155. Anikeeva N, Somersalo K, Sims TN, Thomas VK, Dustin ML, Sykulev Y. Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 2005;102:6437-6442.
156. Zompi S, et al. NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. Nat Immunol 2003;4:565-572.
157. Andre P, et al. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur J Immunol 2004;34:961-971.
158. Wu J, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999;285:730-732.
159. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol 2003;4:557-564.
160. Watzl C, Stebbins CC, Long EO. NK cell inhibitory receptors prevent tyrosine phosphorylation of the activation receptor 2B4 (CD244). J Immunol 2000;165:3545-3548.
161. Tkaczyk C, Beaven MA, Brachman SM, Metcalfe DD, Gilfillan AM. The phospholipase C gamma 1-dependent pathway of Fc epsilon RI-mediated mast cell activation is regulated independently of phosphatidylinositol 3-kinase. J Biol Chem 2003;278:48474-48484.
162. Parolini S, et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 2000;192:337-346.
163. Sivori S, et al. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci USA 2002;99:4526-4531.
164. Lee KM, et al. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J Exp Med 2004;199:1245-1254.
165. Roncagalli R, et al. Negative regulation of natural killer cell function by EAT-2, a SAP-related adaptor. Nat Immunol 2005;6:1002-1010.
166. Tassi I, Colonna M. The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells. J Immunol 2005;175:7996-8002.
167. Jackson MR, Song ES, Yang Y, Peterson PA. Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells. Proc Natl Acad Sci USA 1992;89:12117-12121.
168. Faure M, Barber DF, Takahashi SM, Jin T, Long EO. Spontaneous clustering and tyrosine phosphorylation of NK cell inhibitory receptor induced by ligand binding. J Immunol 2003;170:6107-6114.
169. Stebbins CC, Watzl C, Billadeau DD, Leibson PJ, Burshtyn DN, Long EO. Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol Cell Biol 2003;23:6291-6299.
170. Cella M, et al. Differential requirements for Vav proteins in DAP10- and ITAM-mediated NK cell cytotoxicity. J Exp Med 2004;200:817-823.
171. Cosman D, et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997;7:273-282.
172. Tomasec P, et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000;287:1031.
173. Khakoo SI, et al. Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans. Immunity 2000;12:687-698.
174. Martin MP, Carrington M. Immunogenetics of viral infections. Curr Opin Immunol 2005;17:510-516.
175. Ishido S, et al. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity 2000;13:365-374.
176. Cosman D, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14:123-133.
177. Tomasec P, et al. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol 2005;6:181-188.
178. Arnon TI, et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005;6:515-523.
179. Wu J, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-1070.
180. Takeuchi T, et al. A novel mutation in the FcgammaRIIIA gene (CD16) results in active natural killer cells lacking CD16. Autoimmunity 1999;31:265-271.
181. Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect 2002;4:1545-1558.
182. Fitzgerald-Bocarsly P, Howell DM, Pettera L, Tehrani S, Lopez C. Immediate-early gene expression is sufficient for induction of natural killer cell-mediated lysis of herpes simplex virus type 1-infected fibroblasts. J Virol 1991;65:3151-3160.
183. Weinhold KJ, et al. Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet 1988;1:902-905.
184. Hildreth JE, Hampton R, Halsey NA. Antibody-dependent cell-mediated cytotoxicity can protect PBMC from infection by cell-associated HIV-1. Clin Immunol 1999;90:203-212.
185. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004;172:5598-5605.
186. Scharton-Kersten TM, Sher A. Role of natural killer cells in innate resistance to protozoan infections. Curr Opin Immunol 1997;9:44-51.
187. Igarashi T, et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and
188. Ortaldo JR, Young HA. IL-18 as critical co-stimulatory molecules in modulating the immune response of ITAM bearing lymphocytes. Semin Immunol 2006;18:193-196.
189. von Strandmann EP, et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006;107:1955-1962.
190. Tran AC, Zhang D, Byrn R, Roberts MR. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. J Immunol 1995;155:1000-1009.
191. Preithner S, et al. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 2006;43:1183-1193.
192. Fischer L, et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 2006;34:753-759.
193. Cartron G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-758.
194. Dall'Ozzo S, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-4669.
195. Gluck WL, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004;10:2253-2264.
196. Arnould L, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94:259-267.
197. Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S., Carson WE III. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res 2006;66:517-526.
198. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986;137:245-254.
199. Gasser S, Raulet DH. The DNA damage response arouses the immune system. Cancer Res 2006;66:3959-3962.